drugset / Trial / NCT01726946

A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

NCT01726946

Phase 2 Completed 10 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase 2 study to evaluate the safety and efficacy of two different once daily doses VX-135 in combination with ribavirin in treatment-naïve subjects with chronic hepatitis C

Timeline

Start
2012-11
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule
Subject VX-135 Small molecule